• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care
Rare Disease : Episode 19

Episode 15 - SLE: Expectations As the Drug Market Evolves

Video

Although currently limited, Michelle Petri, MD, MPH, explains that the drug market for treating systemic lupus erythematosus (SLE) is growing. Dr Petri explains that because SLE is a heterogeneous disease that manifests in patients in many different ways, new agents to treat SLE will be classified into a series of different categories.

Dr Petri continues the discussion by exploring the future roles of these new agents which leads the panelists into a conversation about the costs of these treatment options.

Hugh Fatodu, RPh, MBA, and Dr Petri conclude that without proper data that review the long-term outcomes of agents for the treatment of SLE, it is difficult to estimate any economic benefits or advantages.


Related Videos
Danielle Roman, PharmD, BCOP, Allgheny Health Network
Eleanor Perfetto, PhD
Tom Kim, chief medical officer, Sound Long-Term Care Management
Dr Yara Abdou
Erika Hamilton, MD
Dr Jennifer Graff, Dr Joey Mattinly, and Brian Reid Dr Jennifer Graff and Brian Reid | Background image credit: ipopba - stock.adobe.com
© 2026 MJH Life Sciences
AJMC®
All rights reserved.